about
Initiation and continuation of randomized trials after the publication of a trial stopped early for benefit asking the same study question: STOPIT-3 study designOn transcending the impasse of respiratory motion correction applications in routine clinical imaging - a consideration of a fully automated data driven motion control framework.Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications.Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaEffects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trialsPlanning and reporting of quality-of-life outcomes in cancer trials.Learning from failure--rationale and design for a study about discontinuation of randomized trials (DISCO study).Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study[(18)F]fluorodeoxyglucose PET in large vessel vasculitis.Agreements between Industry and Academia on Publication Rights: A Retrospective Study of Protocols and Publications of Randomized Clinical Trials.Prevalence, characteristics, and publication of discontinued randomized trials.Premature Discontinuation of Randomized Trials in Critical and Emergency Care: A Retrospective Cohort Study.Upregulation of Key Molecules for Targeted Imaging and Therapy.Premature Discontinuation of Pediatric Randomized Controlled Trials: A Retrospective Cohort Study.Indium-111 labeled gold nanoparticles for in-vivo molecular targeting.Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours.Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors.The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors.Completion and Publication Rates of Randomized Controlled Trials in Surgery: An Empirical Study.Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice.Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out.1,2,3-Triazoles as amide bond mimics: triazole scan yields protease-resistant peptidomimetics for tumor targeting.Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.The detrimental effect of anti-thyroid drugs on the outcome of radioiodine therapy is not directly due to decreased radioiodine uptake.Radioiodine uptake and thyroid hormone levels on or off simultaneous carbimazole medication: a prospective paired comparison.[18F]FDG-PET of giant-cell aortitis.The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease.18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial.Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene.Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1.Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.
P50
Q24288919-FA6A1184-D65E-4EAF-B55D-0AF9BAE8C4ADQ27320988-BFAD2073-7F7F-4ADD-B974-B257F659FFE6Q33909616-E908612F-E275-43CF-8DE1-A94FF000E7CAQ34987688-73CBE956-2A64-445E-8D2E-E4DCA047D3D2Q35675059-C4C653F9-C570-431A-BC58-34A6BEF6D70CQ36000225-13A7691D-16C4-43DB-A2B4-94AA9D1B4BA9Q36483995-0B68D07C-30BA-47A9-B3FC-310687C20683Q36578624-F9F57B93-0551-432F-B1F0-EF8BFE32CA21Q36913462-EB1FDF39-EB8B-4817-A6F1-A4393261D008Q37046876-2FDBFC6F-2AA6-488B-BFBE-E18151DA1B67Q38392593-128A5FE7-950D-4BD8-863A-8CE95E0144D7Q38607677-C5F41ECC-B8CB-4308-A830-97084463C8CEQ38734454-D439727E-7C51-436B-9163-17EF52428805Q38836845-7AA08699-3034-458F-A440-A221141A9CDDQ38993760-E44D7DFD-DE93-4D5E-9DBF-C27FE12500BFQ39977421-E28A66AB-3FC5-4B1E-BD60-4C280E41CADFQ40182690-8B0E7DFB-87A9-4762-8601-DF8935D3B1ABQ40458844-1418C1F5-4052-4892-9FA5-AA22240EE089Q40578776-6F0183ED-F100-4624-8971-8F7CAAA83F1BQ40616326-38F9ACE0-5DA2-4113-8764-89B8D305D053Q42208202-802D6719-E7AA-4DD1-890C-794AA9F65229Q42905411-BABFF8F9-FF6C-4446-8C32-6585C24F2005Q42957432-B9FC9C1E-E8D7-4E84-901A-FC324CE0D30CQ43420123-CCB05CE5-7494-4AC1-B2D2-DF8051C9F5CDQ44277672-3F5BAAB7-9B55-4B45-A75F-BA14706D0B41Q44676949-CA6D6169-5623-4C42-8C0F-29A2C7BABEBEQ44712034-074A3F3F-F91E-4E44-9CFF-B536DD4E8115Q45190904-CA2CA270-6346-44D4-98CC-A45A8ED09D62Q45265559-A2DA89D7-9A0E-46EB-8525-6E7ECC5FD3CAQ45280728-EDCC91BB-6E6E-4491-9B1B-49B9BA8DD826Q45300713-59F19506-7C46-4917-9CA6-103524859D2DQ45941041-EC7DAE37-70DF-42B1-A4DF-3FEB31A0FD1FQ46003506-A33CBBB5-E7DC-497D-8EB7-81702F91352DQ46111876-3C71A02A-1808-4A41-B864-B5A9CF8B2307Q46195692-BC7F7D6C-CDBB-4C6F-978C-CA78C9A2321DQ46699023-E2DEE912-C450-4D09-A7B1-D56AF9CE934CQ46774676-5453D4CA-9EF2-49E7-96DB-36BDB1A31408Q46897608-30AF6F61-DE69-4B05-BC79-D30DDB451F9EQ47577548-F77471C9-9466-4628-988A-12D16C88DF0DQ47801615-BB2F4864-90B9-4C2A-AB96-0513BA6C3E05
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Martin Walter
@ast
Martin Walter
@en
Martin Walter
@es
Martin Walter
@nl
Martin Walter
@sl
type
label
Martin Walter
@ast
Martin Walter
@en
Martin Walter
@es
Martin Walter
@nl
Martin Walter
@sl
altLabel
Martin A. Walter
@en
prefLabel
Martin Walter
@ast
Martin Walter
@en
Martin Walter
@es
Martin Walter
@nl
Martin Walter
@sl
P1053
B-5203-2017
P106
P21
P31
P3829
P496
0000-0001-6487-5349